Aquestive Therapeutics, Inc. (AQST) Net margin 2017–2025
Aquestive Therapeutics, Inc. (AQST) net profit margin by fiscal year — reported net income divided by reported revenue.
-188.1%FY2025 · since FY2017: -13.4% → -188.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -188.1% | -111.4 pp |
| FY2024 | -76.7% | -61.1 pp |
| FY2023 | -15.6% | +98.6 pp |
| FY2022 | -114.1% | +24.7 pp |
| FY2021 | -138.8% | -17.1 pp |
| FY2020 | -121.7% | +4.3 pp |
| FY2019 | -125.9% | -34.9 pp |
| FY2018 | -91.0% | -77.7 pp |
| FY2017 | -13.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice